DRMA is a stock, not an exchange-traded fund, and its analyst coverage is too sparse to build a meaningful multi-analyst aggregate. A search of reputable trackers shows effectively one current, verifiable price objective: Maxim Group, which has maintained a Buy rating and a $4.00 price target on the shares. TipRanks records Maxim lowering its target from $10 to $4 in early 2026, and Maxim analyst Anthony Vendetti reiterated the $4.00 target and Buy rating in August 2026, when the stock traded near $1.57. Yahoo Finance lists the one-year target estimate at $4.00.
Because only a single current target could be verified from an identifiable analyst and firm, this article treats $4.00 as a publicly discussed price objective rather than an official "analyst consensus." A much higher second figure circulating on some aggregators could not be corroborated across reputable sources and was excluded. Investors should therefore regard $4.00 as one firm's view, not a market-wide forecast.
Dermata Therapeutics closed near $0.66 per share on October 14, 2026, down sharply in a single session and sitting just above its 52-week low of roughly $0.60. Its 52-week high is about $4.66, meaning the $4.00 target sits just below that prior peak. From roughly $0.66, reaching $4.00 implies about 500% upside — by any standard, a very large move rather than a modest or incremental one.
The company is a development-stage and early-commercial dermatology business. It generated essentially no meaningful revenue in recent quarters and has reported recurring net losses, with roughly $4.4 million in cash on its most recent balance sheet. Reaching $4.00 would most plausibly require a credible commercialization inflection — meaningful Tome product revenue, a reduction in cash burn, or a financing that does not heavily dilute existing holders.
The stock trades near its 52-week low of about $0.60 after a steep single-day decline, a bearish technical backdrop. The $4.00 target is just below the 52-week high of roughly $4.66, meaning the stock would need to recover almost its entire prior-year range. The $1.00 psychological level and prior consolidation zones in the $1.00–$1.50 range represent early resistance on any recovery path. With a 52-week range of roughly $0.60 to $4.66, DRMA remains in a broad downtrend that would need to reverse decisively before a sustained move toward $4.00 becomes technically credible.
Analyst price targets generally reflect a research horizon of roughly 12 months, though this single-target case makes any timing uncertain. Key items to monitor include quarterly earnings and cash-burn disclosures, the Tome product launch and any early revenue or sell-through figures, financing announcements and their dilution impact, analyst target changes, and Nasdaq listing-status updates. A sharp move toward the target would likely depend on visible commercial traction rather than technical momentum alone.
For traders following volatile, thinly covered names such as DRMA, Tickeron's AI Daily Buy/Sell Signals offers a data-driven way to keep pace. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use it to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart review alone. Explore the signals to see how AI-driven screening can support your own research process.
The question of whether DRMA can reach $4.00 rests on a single, very distant price objective rather than a broad analyst consensus. At roughly $0.66, the required move is enormous — about 500% — and the company remains a pre-revenue micro-cap with meaningful cash-burn and dilution risk, a history of reverse splits, and a weak technical backdrop. The strongest supports are the maintained Buy rating, the pivot to DTC skincare, and the potential for an operational inflection, while the principal obstacles are the absence of meaningful revenue and the ongoing need for capital. Investors should weigh the single-firm nature of the target and monitor commercial execution, financing, and cash position before drawing any conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DRMA has been loosely correlated with PVLA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if DRMA jumps, then PVLA could also see price increases.
| Ticker / NAME | Correlation To DRMA | 1D Price Change % | ||
|---|---|---|---|---|
| DRMA | 100% | -8.09% | ||
| PVLA - DRMA | 40% Loosely correlated | +2.15% | ||
| PLRX - DRMA | 32% Poorly correlated | -2.92% | ||
| KRRO - DRMA | 28% Poorly correlated | -1.59% | ||
| KALA - DRMA | 26% Poorly correlated | +0.58% | ||
| CRBP - DRMA | 26% Poorly correlated | -3.05% | ||
More | ||||